This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous thromboembolism (CAT). A total of 2,300 patients with active cancer and objectively confirmed venous thromboembolism will be randomized in a 1:1 ratio to receive edoxaban-based or apixaban-based treatment. The primary objective is to determine whether edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to net adverse clinical events (NACE), defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria.

Start Date01 Nov 2026

Sponsor / Collaborator

Samsung Medical Center

[+8]

TCTR20260920004

/ Not yet recruitingPhase 1

A Single Dose, Randomized, Open-label, Two-treatment, Four-period, Two-sequence, Replicate Crossover Bioequivalence Study of Generic Edoxaban 60 mg Film-coated Tablets and Reference Product (Lixiana 60 mg) in Healthy Thai Volunteers under Fasting Conditions

Start Date12 Oct 2026

Sponsor / Collaborator-

TCTR20260814003

/ Not yet recruitingPhase 1

A Bioequivalence study of a randomized, open-label, single dose, full replicated crossover design with four-period, two-treatment, and two-sequence of Edoxaban tablets 60 mg relative to LIXIANA tablets 60 mg in healthy Thai participants under fasting condition

Start Date10 Sep 2026

Sponsor / Collaborator

Bio-Innova Co. Ltd.

100 Clinical Results associated with Edoxaban Tosylate

100 Translational Medicine associated with Edoxaban Tosylate

100 Patents (Medical) associated with Edoxaban Tosylate

2,545

Literatures (Medical) associated with Edoxaban Tosylate

31 Dec 2026·Future Science OA

Real-world evidence on off-label underdosing of direct oral anticoagulants in Asian patients with atrial fibrillation: prescribing patterns, determinants, and outcomes

Article

Author: Wattanasombat, Supharat ; Bvornphattanasakul, Purachai ; Phatthanasobhon, Sirayut ; Koonlachad, Tanaphorn ; Pholprasittito, Supisara ; Mongkhon, Pajaree ; Bureekam, Natrawee

BACKGROUND:

Off-label underdosing of direct oral anticoagulants (DOACs) is common among Asian patients with atrial fibrillation (AF), partly reflecting concerns about bleeding, yet Southeast Asian data remain limited. This study aimed to characterize DOAC dosing patterns, identify predictors of off-label underdosing, and evaluate associated effectiveness and safety outcomes.

METHODS:

We conducted a retrospective cohort using electronic health records (EHRs) from two tertiary hospitals in Thailand (2015-2023). Incident AF patients initiating dabigatran, rivaroxaban, apixaban, or edoxaban were included. Doses were classified as on-label, underdosed, or overdosed based on guideline criteria. Propensity score-based inverse probability of treatment weighting (PS-IPTW) Cox proportional hazards regression models was used to evaluate ischemic stroke or systemic embolism (ISSE) and bleeding outcomes.

RESULTS:

Among 553 patients, 20.4% were underdosed, 6.3% overdosed, and 73.2% received on-label dosing. Rivaroxaban was most frequently underdosed. Older age and diabetes mellitus independently predicted underdosing. Compared to on-label dosing, underdosing was not associated with ISSE (adjusted hazard ratio [aHR] 0.48, 95% CI 0.11-2.16; p = 0.336) or bleeding (aHR 1.06, 95% CI 0.30-3.73; p = 0.924).

CONCLUSIONS:

Off-label underdosing occurred in one-fifth of patients but was not associated with significant differences in ISSE or bleeding. Larger, prospective studies in broader Asian and non-Asian populations are warranted.

31 Dec 2026·RENAL FAILURE

Kidney injury associated with direct oral anticoagulants: a comparative study of direct thrombin inhibitors and factor Xa inhibitors based on literature and database analysis

Article

Author: Li, Xiang ; Chen, Songhua ; Wang, Xia ; Guo, Ren ; Shi, Can ; Wu, Tian

While direct oral anticoagulants (DOACs) are widely used, limited real-world studies have explored kidney injury linked to DOACs, particularly differences between direct thrombin inhibitors (DTIs) and factor Xa inhibitors (FXaIs). We conducted a comprehensive analysis of kidney injury cases from the FDA Adverse Event Reporting System (FAERS, 2008-2024) and systematically reviewed published case reports, comparing DTIs (dabigatran) with FXaIs (rivaroxaban, apixaban, edoxaban). Among 8,116 reports of suspected DOAC-associated kidney injury, 1,784 were linked to DTIs and 6,332 to FXaIs. Significant reporting rates were observed for DTIs [reporting odds ratio (ROR) = 2.081, 95% CI: 1.979-2.189; proportional reporting ratio (PRR) = 2.044, CI: 1.947-2.147)] and FXaIs (ROR = 1.483, 95% CI: 1.444-1.523; PRR = 1.472, CI: 1.434-1.510). Notably, substantial intra-class variation existed among FXaIs, with edoxaban showing the highest risk signal (ROR = 4.453, 95% CI: 4.021-4.932; PRR = 4.212, 95% CI: 3.831-4.632). Multivariable logistic regression analysis confirmed that significantly lower kidney injury reporting disproportionality signals with FXaIs versus DTIs after adjustment (ROR = 0.687, 95% CI: 0.650-0.727, P < 0.001). Analysis of 32 detailed cases revealed distinct clinical patterns: DTI-associated injury featured higher proteinuria rates (P = 0.029), while FXaI-associated injury occurred more frequently in settings of polypharmacy (P = 0.006) and was associated with poorer renal recovery (P = 0.023). This study demonstrates distinct kidney injury risks among DOAC classes and individual agents, with DTIs and edoxaban showing particularly strong signals. These findings emphasize the need for individualized DOAC selection and enhanced renal monitoring in clinical practice.

01 Nov 2026·CURRENT PROBLEMS IN CARDIOLOGY

Device-detected atrial fibrillation after ARTESiA and NOAH-AFNET 6: from episode burden to net clinical benefit

Review

Author: Llerena-Velastegui, Jordan ; Jimbo-Sotomayor, Ruth ; Zambrano-Herdoiza, Jose ; Chavez-Ruales, Jose

Device-detected atrial high-rate episodes and subclinical atrial fibrillation occupy an intermediate state between an electronic signal and clinically documented atrial fibrillation. ARTESiA showed that apixaban reduced stroke or systemic embolism compared with aspirin while increasing major bleeding. NOAH-AFNET 6 found no significant reduction in its broader composite of cardiovascular death, stroke, or systemic embolism with edoxaban and more death or major bleeding. Together, the trials indicate a low untreated stroke rate near 1% per year, reduced ischemic stroke with direct oral anticoagulation, and increased major bleeding. Treatment depends on absolute risk, outcome severity, and competing harm rather than a binary reading of statistical significance. This narrative review distinguishes randomized evidence, formal guideline recommendations, the 2026 American College of Cardiology Scientific Statement, and the authors' proposed framework, integrating diagnostic certainty, device source, episode characteristics and trajectory, prior stroke or transient ischemic attack, vascular and atrial substrate, bleeding susceptibility, and patient priorities. After rhythm confirmation, higher thromboembolic risk-including subgroup evidence after prior stroke or transient ischemic attack-may favor consideration of anticoagulation when bleeding risk is acceptable; uncertain signals, isolated short episodes, lower clinical risk, or substantial competing harm may favor continued surveillance. The six-minute trial eligibility criterion, episode duration, and device type are not independently validated universal treatment triggers, and no universally validated burden threshold exists. The proposed staged net-clinical-benefit framework is conceptual and hypothesis-generating, has not been prospectively or externally validated, and is not intended as a universal prescriptive treatment algorithm.

News (Medical) associated with Edoxaban Tosylate

31 Jul 2026

·www.biospace.com

Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results

Revenue increased 21.1% to 574.7 billion yen year-over-year driven by Enhertu ® and Datroway ® Fiscal year 2026 guidance for revenue and operating profit revised upward Conference call to take place on Friday, July 31 at 5:30 pm Japan Standard Time TOKYO--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) reported financial results for the first quarter of fiscal year 2026, ending June 30, 2026. “Daiichi Sankyo delivered strong revenue growth in the first quarter of fiscal year 2026 as we began execution of our new Five-Year Business Plan,” said Hiroyuki Okuzawa, President and CEO of Daiichi Sankyo. “Three new U.S. approvals for Enhertu and Datroway were received in a single week in May, underscoring the continued strength of our portfolio where we anticipate delivering more than 20 new indications across five medicines by 2030. These results reinforce the durability of our growth trajectory and support our outlook for fiscal 2026 and beyond.” Q1 FY2026 Results Global revenue increased 21.1% year-over-year to 574.7 billion yen, driven by the company’s global oncology products. Operating profit decreased 12.0% year-over-year to 85.1 billion yen, primarily due to EU Specialty Business restructuring expenses. Global revenue from oncology products was driven by Enhertu ® and Datroway ® , the company's flagship antibody drug conjugates (ADCs). Enhertu revenue, including milestone payments, was 239.8 billion yen, a 48.9% increase. Datroway revenue, including milestone payments, was 23.9 billion yen, a 176.4% increase. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Revenue from the Japan Business was 120.0 billion yen, driven by Lixiana ® and Tarlige ® . ASCA (Asia, South and Central America) Business revenue was 68.7 billion yen, driven by Enhertu. EU Specialty Business revenue was 74.7 billion yen, driven by Lixiana and Nilemdo ® /Nustendi ® . Full fiscal year 2026 guidance has been revised upward from the forecast issued in May 2026. Global revenue is anticipated to increase from 2.28 to 2.34 trillion yen, driven by stronger sales anticipated in the U.S. and favorable foreign exchange rates. Operating profit is anticipated to increase from 315.0 to 320.0 billion yen. Further details on financial performance can be found in the Financial Results Presentation Material . Daiichi Sankyo will host an investor and media conference call and webcast to discuss Q1 FY2026 results on Friday, July 31 at 5:30 pm Japan Standard Time. Q4 FY2025 Results Revision Operating profit has increased from 229.1 billion yen to 258.0 billion yen. Following the announcement of the Q4 FY2025 financial results on May 11, 2026, the Company identified an error in the aggregation process for selling, general and administrative (SG&A) expenses. As a result of the decrease in SG&A expenses, operating profit has been revised upward. Portfolio and Pipeline Highlights Daiichi Sankyo continued to advance its portfolio and pipeline with several milestones across its oncology portfolio, demonstrating momentum towards its goal of launching 20 new indications across five medicines by 2030. Three new breast cancer indications were approved within one week in the U.S. for Enhertu and Datroway in May 2026, including simultaneous approval of two new indications for Enhertu in the neoadjuvant and adjuvant HER2 positive early breast cancer setting based on the DESTINY-Breast11 and DESTINY-Breast05 phase 3 trials, followed by one new indication for Datroway in the first-line metastatic triple negative breast cancer (TNBC) setting for patients not candidates for immunotherapy based on the TROPION-Breast02 phase 3 trial. Datroway received approval in the EU for the same TNBC indication and Enhertu received a positive CHMP opinion for the first-line treatment of HER2 positive metastatic breast cancer based on the DESTINY-Breast09 phase 3 trial in July 2026. A Biologics License Application (BLA) was accepted and granted priority review in the U.S. in April 2026 for ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or after platinum-based chemotherapy, with a Prescription Drug User Fee Act (PDUFA) date of October 10, 2026. Additional regulatory approvals were received in June 2026 for medicines in other major countries/regions. Enhertu received approval in the EU for a HER2 positive metastatic tumor agnostic indication and Vanflyta ® was approved in China in the newly diagnosed setting of FLT3 -ITD positive acute myeloid leukemia (AML). Data from more than 25 abstracts across multiple cancers were presented at the 2026 American Society of Clinical Oncology (#ASCO26) in June 2026. Medicine Indication Q1 FY2026 Update Enhertu Breast Enhertu Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer ( May 2026 ) Enhertu Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer ( July 2026 ) Tumor Agnostic Enhertu Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors ( June 2026 ) Datroway Breast Datroway Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates ( May 2026 ) Datroway Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy ( July 2026 ) I-DXd Lung Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy ( April 2026 ) Vanflyta AML Vanflyta Approved in China as First and Only FLT3 Inhibitor for Patients with Newly Diagnosed FLT3 -ITD Positive AML ( June 2026 ) Pipeline Various Daiichi Sankyo Showcases Progress Across Industry-Leading Oncology Portfolio with Latest Research Updates at ASCO ( May 2026 ) Corporate Highlights Daiichi Sankyo announced its next Five-Year Business Plan (FY2026 - FY2030) in May 2026 outlining how the company plans to deliver more than 2.3 trillion yen in oncology revenue by 2030 and be a global top five oncology company by 2035 as part of its larger 2035 Vision to be recognized as a “trusted healthcare innovator transforming the lives of people through our science and technology.” As part of the company’s continued transformation into a global oncology company, Daiichi Sankyo announced in April 2026 that it will transfer in stages all of its shares of Daiichi Sankyo Healthcare Co., Ltd, its over-the-counter drug business in Japan, to Suntory Holdings Limited. The deal is estimated to be completed by June 2029. About Daiichi Sankyo Daiichi Sankyo (TSE: 4568) is a global healthcare company committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world. With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society. For more information, please visit . Forward-Looking Statements Management strategies and plans, financial forecasts, future projections and policies, and R&D information that Daiichi Sankyo discloses in this material are all classified as Daiichi Sankyo’s future prospects. These forward-looking statements, including words such as “anticipate,” “estimated,” “favorable,” “goal,” “momentum,” “outlook,” “trajectory,” were determined by Daiichi Sankyo based on information obtained as of today with certain assumptions, premises and future forecasts, and thus, there are various inherent risks as well as uncertainties involved. As such, please note that actual results of Daiichi Sankyo may diverge materially from the outlook of Daiichi Sankyo or the content of this material. Furthermore, there is no assurance that any forward-looking statements in this material will be realized. Regardless of the actual results or facts, Daiichi Sankyo is not obliged and does not have in its policy the duty to update the content of this material from the date of this material onward. Some of the compounds under discussion are investigational agents and are not approved by the FDA or any other regulatory agency worldwide as a treatment for indications under investigation. Efficacy and safety have not been established in areas under investigation. There are no guarantees that these compounds will become commercially available in indications under investigation. Daiichi Sankyo takes reasonable care to ensure the accuracy of the content of this material but shall not be obliged to guarantee the absolute accuracy, appropriateness, completeness and feasibility, etc. of the information described in this material. Furthermore, any information regarding companies, organizations or any other matters outside the Daiichi Sankyo Group that is described within this material has been compiled or cited using publicly available information or other information, and Daiichi Sankyo has not performed in-house inspection of the accuracy, appropriateness, completeness and feasibility, etc. of such information, and does not guarantee the accuracy thereof. The information described in this material may be changed hereafter without notice. Accordingly, this material or the information described herein should be used at your own judgment, together with any other information you may otherwise obtain. This material does not constitute a solicitation of application to acquire or an offer to sell any security in the United States, Japan or elsewhere. This material disclosed here is for reference purposes only. Final investment decisions should be made at your own discretion. Daiichi Sankyo assumes no responsibility for any damages resulting from the use of this material or its content, including without limitation damages related to the use of erroneous information. Contacts MEDIA CONTACTS: Global: Jennifer Brennan jennifer.brennan@daiichisankyo.com +1 908 900 3183 (mobile) INVESTOR RELATIONS CONTACT: DaiichiSankyoIR_jp@daiichisankyo.com Japan: DS-PR_jp@daiichisankyo.com

Drug ApprovalImmunotherapyPhase 3ASCOFinancial Statement

08 Jul 2026

·www.fiercepharma.com

Foreign drugmaker caught faking doctors’ petition to evade China’s price cut scheme

Amid an ongoing expansion of China’s volume-based procurement (VBP) scheme to lower drug costs, the Chinese government has singled out a fraud case involving a foreign originator drug in a warning to the industry. In an attempt to influence whether a drug gets selected for price bidding, a foreign drug innovator faked doctors’ signatures in a petition, China’s National Healthcare Security Administration (NHSA) said in a post (Chinese) on Tuesday. Among the 78 signatures from 31 hospitals, over 80% were found to be doctored. Some signatures were forged by sales representatives, some used misappropriated images from other sources, and some pointed to individuals that do not exist, according to the agency. As for the few signatures that the experts themselves indeed wrote, the doctors were mostly tricked into signing the document under the guise of survey questionnaires or post-sales follow-up, the agency said. The drug has since been included in the latest VBP batch of 65 drug varieties, which together represent a total market value of nearly 60 billion Chinese yuan ($8.8 billion), according to the NHSA. The VBP, now in its 12th round, is a government-led drug-buying program targeting off-patent medicines. Under the program, generics and the originators offer price cuts to secure procurement contracts with hospitals. The government unveiled the latest list on June 23 and is now in the bidding process. In a statement to local news outlet The Paper , Novartis confirmed it was not the unnamed drugmaker flagged in the NHSA alert. The Swiss pharma’s blockbuster heart failure treatment Entresto (sacubitril/valsartan) is one of the biggest products in this VBP round. According to local reports, Entresto and its generics generated more than 6 billion yuan of end-market sales ($880 million) at public hospitals in China last year, with the Novartis originator accounting for more than 90%. The VBP program now threatens to split up that huge market by rewarding significant shares to companies that offer lower prices. In what’s slated to be an über-competitive bidding process, more than 30 Entresto generics competitors are vying for a place under VBP, according to local drug intelligence database DXY Insight. As part of the largest patent expiry in Novartis’ history, Entresto lost its U.S. market exclusivity last year and has seen major sales declines since. Some uncertainties remain for VBP’s potential impact on Entresto. The Novartis drug is among eight products that carry an asterisk, which indicates ongoing patent disputes. A few days before the revelation of the latest VBP list last month, China’s National Intellectual Property Administration doled out a five-year patent-term extension to Entresto to make up for time lost during its drug regulatory review process, effectively pushing back the expiration of its core patent to November 2031. In a new rule introduced into VBP this time, generic rivals to those asterisked drugs must submit a declaration of non-infringement or be removed from procurement platforms. Takeda’s angiotensin II receptor blocker Edarbi (azilsartan medoxomil) and acid blocker Takecab (vonoprazan fumarate), Eli Lilly’s JAK inhibitor Olumiant, Daiichi Sankyo’s factor Xa inhibitor edoxaban and AstraZeneca’s Xigduo XR (dapagliflozin and metformin extended release) are also included in VBP despite ongoing patent disagreements. Takeda, Bayer and Eisai have also denied they were the company in the NHSA’s announcement, according to The Paper. Bayer’s drospirenone/ethinyl estradiol oral contraceptive, known commercially as Yaz or Yasmin, and its imaging contrast agent Ultravist (iopromide) are included for VBP bidding against generics. Eisai has anti-vertigo medication Merislon (betahistine) and anti-seizure med Fycompa (perampanel) on the list. In addition to the companies above, the 65-item roster includes brand-name products from almost all major pharmas, including Astellas, Fresenius Kabi, GSK, Johnson & Johnson, Pfizer, Merck & Co., Merck KGaA, Otsuka, Sanofi and Servier. Among the smaller firms involved are Cheplapharm, Dr. Falk Pharma and Grünenthal from Germany; Japan’s Maruishi Pharmaceutical, Sumitomo Pharma, LTL Pharma and Minophagen Pharmaceutical; as well as the Wellcome Foundation and Tillotts Pharma in Switzerland.

29 Aug 2025

·www.einpresswire.com

January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Addyi (flibanserin) Drug hypersensitivity The "Contraindications", "Warnings and Precautions", "Adverse Reactions", and "Medication Guide" sections of the labeling were updated in September 2021 to include hypersensitivity reactions. Addyi labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua (insulin glargine and lixisenatide) Trulicity (dulaglutide) Victoza (liraglutide) Xultophy (insulin degludec and liraglutide) Drug-induced liver injury The "Adverse Reactions" section of the liraglutide and dulaglutide labeling was updated in June 2022 to include information about elevations of liver enzymes. Example: Trulicity labeling FDA determined that no action is necessary at the time for lixisenatide, exenatide, and semaglutide based on available information. Alcohol-based hand sanitizers Exposure via inhalation FDA determined that no action is necessary at the time based on available information. A FDA Drug Safety Communication was issued on June 16, 2021. Amlodipine and Levamlodipine Products Azor (amlodipine and olmesartan medoxomil ) Caduet (amlodipine besylate and atorvastatin calcium) Conjupri (levamlodipine maleate) Consensi (amlodipine besylate and celecoxib) Exforge (amlodipine and valsartan) Exforge HCT (amlodipine/valsartan and hydrochlorothiazide) Lotrel (amlodipine besylate and benazepril hydrochloride) Katerzia (amlodipine benzoate) Norvasc (amlodipine besylate) Prestalia (amlodipine besylate and perindopril arginine) Tribenzor (amlodipine besylate/olmesartan medoxomil and hydrochlorothiazide) Twynsta (amlodipine and telmisartan) Non-cardiogenic pulmonary edema FDA determined that no action is necessary at the time based on available information. Avonex (interferon beta-1a) Betaseron (interferon beta-1b) Extavia (interferon beta-1b) Plegridy (pegylated interferon beta-1a) Rebif (interferon beta-1a) Injection site abscess FDA is evaluating the need for regulatory action. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Scleroderma FDA determined that no action is necessary at the time based on available information. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Cholangitis sclerosing The "Adverse Reactions" section of the Keytruda (pembrolizumab) labeling was updated in August 2021 to include sclerosing cholangitis. Example: Keytruda labeling FDA determined that no action is necessary at the time for Bavencio (avelumab), Imfinzi (durvalumab), Libtayo (cemiplimab-rwlc), Opdivo (nivolumab), and Tecentriq (atezolizumab) based on available information. Chloroquine Generic products containing chloroquine Phospholipidosis The “Warnings” section of the labeling was updated in May 2022 to include information about phospholipidosis. Eliquis (apixaban) Pradaxa (dabigatran etexilate mesylate) Savaysa (edoxaban tosylate) Xarelto (ribaroxaban) Generic products containing dabigatran etexilate mesylate Generic products containing ribaroxaban Menorrhagia The “Use in Specific Populations” section was updated April 2021 to add language to describe the risk of clinically significant uterine bleeding in females of reproductive potential. Eliquis label Pradaxa label Savaysa label Xarelto label Depakote (divalproex sodium) Depakote ER (divalproex sodium) Stavzor (valproic acid) Generic products containing divalproex sodium Generic products containing valproic acid Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated in November 2021 to include tubulointerstitial nephritis. Example: Depakote labeling Dupixent (dupilumab) Alopecias FDA is evaluating the need for regulatory action. H.P. Acthar Gel (corticotropin) Anaphylactic and anaphylactoid responses The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include anaphylaxis. Acthar Gel labeling H.P. Acthar Gel (corticotropin) Cardiac arrhythmias The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include atrial fibrillations and palpitations. Acthar Gel labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Verzenio (abemaciclib) Second primary malignancy FDA determined that no action is necessary at the time based on available information. Lynparza (olaparib) Drug-induced liver injury FDA determined that no action is necessary at the time based on available information. Ocrevus (ocrelizumab) Autoimmune colitis The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Medication Guide" sections of the labeling were updated in August 2022 to include colitis. Ocrevus labeling Poteligeo (mogamulizumab-kpkc) Acute kidney injury The "Warnings and Precautions" section of the labeling was updated in March 2022 to include glomerulonephritis. Poteligeo labeling Ravicti (glycerol phenylbutyrate) Product labeling issue regarding stability and instructions for administration The container label, carton label, "Medication Guide", and sections of the Prescribing Information ("Dosage and Administration" and "Patient Counseling Information") were updated in September 2021 to enhance the instructions for administration. Ravicti labeling Spravato (esketamine) Hypertensive crisis FDA determined that no action is necessary at the time based on available information. Tremfya (guselkumab) Device use errors resulting in possible missed or partial doses The Tremfya One Press Instructions for Use (IFU) and carton labeling was updated in June 2023 to mitigate medication errors, such as underdose or no dose delivered. Tremfya labeling Trulance (plecanatide) Drug hypersensitivity The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include skin itching, hives, and rash. Trulance Label Trulance (plecanatide) Vomiting The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include vomiting. Trulance Label Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

100 Deals associated with Edoxaban Tosylate

External Link

KEGG	Wiki	ATC	Drug Bank
D09710	Edoxaban Tosylate	B01AF03	DB09075

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Thromboembolism	Canada	Daiichi Sankyo, Inc.	04 Nov 2016
Atrial Fibrillation	European Union	Daiichi Sankyo Europe GmbH	19 Jun 2015
Atrial Fibrillation	Iceland	Daiichi Sankyo Europe GmbH	19 Jun 2015
Atrial Fibrillation	Liechtenstein	Daiichi Sankyo Europe GmbH	19 Jun 2015
Atrial Fibrillation	Norway	Daiichi Sankyo Europe GmbH	19 Jun 2015
Atrial Fibrillation	United Kingdom	Daiichi Sankyo UK Ltd.	19 Jun 2015
Recurrent deep vein thrombosis	European Union	Daiichi Sankyo Europe GmbH	19 Jun 2015
Recurrent deep vein thrombosis	Iceland	Daiichi Sankyo Europe GmbH	19 Jun 2015
Recurrent deep vein thrombosis	Liechtenstein	Daiichi Sankyo Europe GmbH	19 Jun 2015
Recurrent deep vein thrombosis	Norway	Daiichi Sankyo Europe GmbH	19 Jun 2015
Recurrent deep vein thrombosis	United Kingdom	Daiichi Sankyo UK Ltd.	19 Jun 2015
Systemic embolism	Switzerland	Daiichi Sankyo (Schweiz) AG	31 Mar 2015
Embolism	United States	Daiichi Sankyo, Inc.	08 Jan 2015
Stroke	United States	Daiichi Sankyo, Inc.	08 Jan 2015
Venous Thromboembolism	Japan	Daiichi Sankyo Co., Ltd.	26 Sep 2014
Pulmonary Embolism	Japan	Daiichi Sankyo Co., Ltd.	22 Apr 2011
Venous Thrombosis	Japan	Daiichi Sankyo Co., Ltd.	22 Apr 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute myocardial infarction	Phase 3	Brazil	Daiichi Sankyo Co., Ltd.	14 Sep 2021
Coronary Artery Disease	Phase 3	Brazil	Daiichi Sankyo Co., Ltd.	14 Sep 2021
Short Chain Acyl CoA Dehydrogenase Deficiency	Phase 3	Brazil	Daiichi Sankyo Co., Ltd.	14 Sep 2021
Chronic thromboembolic pulmonary hypertension	Phase 3	Japan	Daiichi Sankyo Co., Ltd.	08 Feb 2021
COVID-19	Phase 3	Belgium	Daiichi Sankyo Europe GmbH	21 Jan 2021
COVID-19	Phase 3	Italy	Daiichi Sankyo Europe GmbH	21 Jan 2021
COVID-19	Phase 3	Switzerland	Daiichi Sankyo Europe GmbH	21 Jan 2021
Aortic Valve Stenosis	Phase 3	Netherlands	Daiichi Sankyo Co., Ltd.	01 Aug 2019
Heart Diseases	Phase 3	United States	Daiichi Sankyo Co., Ltd.	15 May 2018
Heart Diseases	Phase 3	Austria	Daiichi Sankyo Co., Ltd.	15 May 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03718559 (EPIC-CAD, Pubmed \| Europace)	Phase 3	Coronary Artery Disease \| Atrial Fibrillation	1,040	Edoxaban monotherapy	hkxqqnvckh(euglgbnbqv) = nfhozjrwkm jqdhzxpube (hwhiyuxloc )	Positive	01 Oct 2026
				Edoxaban plus a single antiplatelet agent	hkxqqnvckh(euglgbnbqv) = knsuafutuj jqdhzxpube (hwhiyuxloc )
NCT04542408 (HERO-19, Pubmed \| JAMA Netw Open)	Phase 3	COVID-19	139	Therapeutic anticoagulation using low-molecular-weight heparin (LMWH) and edoxaban	ersvbljfea(jtexixrmla) = cwbcbhsfdu ubzfmvhixq (xltbjfkkjr ) View more	Negative	23 Sep 2026
				Prophylactic anticoagulation using low-molecular-weight heparin (LMWH) and placebo	ersvbljfea(jtexixrmla) = rtaiygllgh ubzfmvhixq (xltbjfkkjr ) View more
ENVISAGE-TAVI AF (ESC2026)	Not Applicable	Atrial Fibrillation	1,377	edoxaban or vitamin K antagonist (Men receiving concomitant antiplatelet therapy)	huitnvpebs(duuukoinxy): HR = 1.34 (95.0% CI, 0.84 - 2.15) View more	Negative	29 Aug 2026
				edoxaban or vitamin K antagonist (Men)
NCT02943785 (ENVISAGE-TAVI AF, ESC2026)	Phase 3	Atrial Fibrillation	1,377	Edoxaban	slzcwzdrjk(urplrgmypf) = srlffpdnop jktshqosfc (zzqkoxliyn )	Positive	28 Aug 2026
				Vitamin K antagonist	-
ESC2026	Not Applicable	Atrial Fibrillation	115,040	On-label DOAC dosing	qfkrzmeudp(xrdrbwzrrw) = qiehhbdvej fsagfrgzyx (llgqtzjvzl ) View more	Positive	28 Aug 2026
				Off-label DOAC dosing	qfkrzmeudp(xrdrbwzrrw) = xrctlhxuto fsagfrgzyx (llgqtzjvzl ) View more
ISTH2026	Not Applicable	Atrial Fibrillation \| Venous Thrombosis \| Venous Thromboembolism	10	RifabutinEdoxabann + RifabutinEdoxaban	nsmzxnklgw(wgvyewfuco) = msrehndhrr ccxmkadxqj (fnevgwkdui ) View more	Positive	15 Jul 2026
ISTH2026	Not Applicable	Atrial Fibrillation \| Venous Thromboembolism	524	Edoxaban	gfzvziszoo(wjrbikfldn) = xgbqxzgwqk aksbgtnloy (obzjqqibnj ) View more	Positive	13 Jul 2026
NCT05869591 (ISTH2026)	Phase 1	Liver Cirrhosis	37	Edoxaban 60 mg OD	cgpqchqqbe(eehexqdtzi) = nklitlndux yaxseviocy (psqwuzaoke ) View more	Positive	13 Jul 2026
				Apixaban 5 mg BID	cgpqchqqbe(eehexqdtzi) = xsxxvlvgly yaxseviocy (psqwuzaoke ) View more
ISRCTN57583139 (The New Horizons Clinical, ISTH2026)	Phase 4	Breast Feeding	4	Edoxaban 60mg daily	hngrqbhcua(hsvbqbvacz) = uiddanjgcs ukwpbckpax (yyfnstbvib ) View more	Positive	12 Jul 2026
NCT05869591 (EASL2026)	Phase 2	Liver Cirrhosis	42	Edoxaban 60 mg OD	tzgbvexdjd(fqvosooimr) = the reduction in DD was −32% with edoxaban (p = 0.08) and −22% with apixaban (p < 0.05). Patients with thrombocytopenia exhibited less DD reduction compared to those with platelets ≥150 G/L (−6% versus −37%; p < 0.05). ykqbyzogoe (fxfcrhguuc )	Positive	27 May 2026
				Apixaban 5 mg BID

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis